This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

BZAM Past Earnings Performance

Past criteria checks 0/6

BZAM has been growing earnings at an average annual rate of 10.4%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 54.1% per year.

Key information

10.4%

Earnings growth rate

30.7%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate54.1%
Return on equity-130.4%
Net Margin-129.2%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How BZAM makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:Z6A Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2382-106430
30 Jun 2371-97390
31 Mar 2363-40340
31 Dec 2249-35290
30 Sep 2242-33260
30 Jun 2239-40280
31 Mar 2235-66280
31 Dec 2130-39280
30 Sep 2128-48271
30 Jun 2123-109261
31 Mar 2115-85261
31 Dec 2013-171351
30 Sep 209-301481
30 Jun 209-246612
31 Mar 2011-254712
31 Dec 1911-195722
30 Sep 1910-69702
30 Jun 197-60582
31 Mar 194-52493
01 Jan 192-45413
30 Sep 180-33293
30 Jun 180-24223
31 Mar 180-18172
31 Dec 170-13141

Quality Earnings: Z6A is currently unprofitable.

Growing Profit Margin: Z6A is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Z6A is unprofitable, but has reduced losses over the past 5 years at a rate of 10.4% per year.

Accelerating Growth: Unable to compare Z6A's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: Z6A is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).


Return on Equity

High ROE: Z6A has a negative Return on Equity (-130.4%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/05 15:00
End of Day Share Price 2024/05/08 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BZAM Ltd. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tamy ChenBMO Capital Markets Equity Research
Christopher CareyBofA Global Research
Derek DleyCanaccord Genuity